|
1
|
Shigematsu H, Yoshida K, Sanada Y, Osada
S, Takahashi T, Wada Y, Konishi K, Okada M and Fukushima M:
Rapamycin enhances chemotherapy-induced cytotoxicity by inhibiting
the expressions of TS and ERK in gastric cancer cells. Int J
Cancer. 126:2716–2725. 2010.
|
|
2
|
Ohtsu A: Chemotherapy for metastatic
gastric cancer: Past, present and future. J Gastroenterol.
43:256–264. 2008. View Article : Google Scholar
|
|
3
|
Ajani JA, Moiseyenko VM, Tjulandin S,
Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi
E, et al V-325 Study Group: Clinical benefit with docetaxel plus
fluorouracil and cisplatin compared with cisplatin and fluorouracil
in a phase III trial of advanced gastric or gastroesophageal cancer
adenocarcinoma: The V-325 Study Group. J Clin Oncol. 25:3205–3209.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee KH, Hur HS, Im SA, Lee J, Kim HP, Yoon
YK, Han SW, Song SH, Oh DY, Kim TY, et al: RAD001 shows activity
against gastric cancer cells and overcomes 5-FU resistance by
downregulating thymidylate synthase. Cancer Lett. 299:22–28. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Benson AB III: New approaches to the
adjuvant therapy of colon cancer. Oncologist. 11:973–980. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Longley DB, Harkin DP and Johnston PG:
5-fluorouracil: Mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sasaki E, Tominaga K, Kuwamura H, Watanabe
T, Fujiwara Y, Oshitani N, Higuchi K and Arakawa T: Synergistic
antitumor effect of combined 5-fluorouracil (5-FU) with
5-chloro-2,4-di-hydroxypyridine on 5-FU-resistant gastric cancer
cells: Possible role of a dihydropyrimidine
dehydrogenase-independent mechanism. J Gastroenterol. 42:816–822.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang J, Liu W, Zhao Q, Qi Q, Lu N, Yang Y,
Nei FF, Rong JJ, You QD and Guo QL: Synergistic effect of
5-fluorouracil with gambogic acid on BGC-823 human gastric
carcinoma. Toxicology. 256:135–140. 2009. View Article : Google Scholar
|
|
9
|
Parker WB and Cheng YC: Metabolism and
mechanism of action of 5-fluorouracil. Pharmacol Ther. 48:381–395.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Peters GJ, van der Wilt CL, van Triest B,
Codacci-Pisanelli G, Johnston PG, van Groeningen CJ and Pinedo HM:
Thymidylate synthase and drug resistance. Eur J Cancer.
31:1299–1305. 1995. View Article : Google Scholar
|
|
11
|
Papamichael D: The use of thymidylate
synthase inhibitors in the treatment of advanced colorectal cancer:
Current status. Stem Cells. 18:166–175. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Murad AM, Santiago FF, Petroianu A, Rocha
PR, Rodrigues MA and Rausch M: Modified therapy with
5-fluo-rouracil, doxorubicin and methotrexate in advanced gastric
cancer. Cancer. 72:37–41. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Douillard JY, Cunningham D, Roth AD,
Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J,
Alakl M, et al: Irinotecan combined with fluorouracil compared with
fluorouracil alone as first-line treatment for metastatic
colorectal cancer: A multicentre randomised trial. Lancet.
355:1041–1047. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chon HJ, Rha SY, Im CK, Kim C, Hong MH,
Kim HR, An JR, Noh SH, Chung HC and Jeung HC: Docetaxel versus
paclitaxel combined with 5-FU and leucovorin in advanced gastric
cancer: combined analysis of two phase II trials. Cancer Res Treat.
41:196–204. 2009. View Article : Google Scholar
|
|
15
|
Choi EJ and Kim GH: 5-Fluorouracil
combined with apigenin enhances anticancer activity through
induction of apoptosis in human breast cancer MDA-MB-453 cells.
Oncol Rep. 22:1533–1537. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hou W, Li Y, Zhang Q, Wei X, Peng A, Chen
L and Wei Y: Triterpene acids isolated from Lagerstroemia speciosa
leaves as alpha-glucosidase inhibitors. Phytother Res. 23:614–618.
2009. View
Article : Google Scholar
|
|
17
|
Kim E, Sy-Cordero A, Graf TN, Brantley SJ,
Paine MF and Oberlies NH: Isolation and identification of
intestinal CYP3A inhibitors from cranberry (Vaccinium macrocarpon)
using human intestinal microsomes. Planta Med. 77:265–270. 2011.
View Article : Google Scholar :
|
|
18
|
Lee MS, Lee CM, Cha EY, Thuong PT, Bae K,
Song IS, Noh SM and Sul JY: Activation of AMP-activated protein
kinase on human gastric cancer cells by apoptosis induced by
corosolic acid isolated from Weigela subsessilis. Phytother Res.
24:1857–1861. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Stohs SJ, Miller H and Kaats GR: A review
of the efficacy and safety of banaba (Lagerstroemia speciosa L.)
and corosolic acid. Phytother Res. 26:317–324. 2012.
|
|
20
|
Miura T, Ueda N, Yamada K, Fukushima M,
Ishida T, Kaneko T, Matsuyama F and Seino Y: Antidiabetic effects
of corosolic acid in KK-Ay diabetic mice. Biol Pharm Bull.
29:585–587. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fukushima M, Matsuyama F, Ueda N, Egawa K,
Takemoto J, Kajimoto Y, Yonaha N, Miura T, Kaneko T, Nishi Y, et
al: Effect of corosolic acid on postchallenge plasma glucose
levels. Diabetes Res Clin Pract. 73:174–177. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Banno N, Akihisa T, Tokuda H, Yasukawa K,
Higashihara H, Ukiya M, Watanabe K, Kimura Y, Hasegawa J and
Nishino H: Triterpene acids from the leaves of Perilla frutescens
and their anti-inflammatory and antitumor-promoting effects. Biosci
Biotechnol Biochem. 68:85–90. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zong W and Zhao G: Corosolic acid
isolation from the leaves of Eriobotrta japonica showing the
effects on carbohydrate metabolism and differentiation of 3T3-L1
adipocytes. Asia Pac J Clin Nutr. 16:346–352. 2007.PubMed/NCBI
|
|
24
|
Chen H, Yang J, Zhang Q, Chen LH and Wang
Q: Corosolic acid ameliorates atherosclerosis in apolipoprotein
E-deficient mice by regulating the nuclear factor-κB signaling
pathway and inhibiting monocyte chemoattractant protein-1
expression. Circ J. 76:995–1003. 2012. View Article : Google Scholar
|
|
25
|
Xu Y, Ge R, Du J, Xin H, Yi T, Sheng J,
Wang Y and Ling C: Corosolic acid induces apoptosis through
mitochondrial pathway and caspase activation in human cervix
adenocarcinoma HeLa cells. Cancer Lett. 284:229–237. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cai X, Zhang H, Tong D, Tan Z, Han D, Ji F
and Hu W: Corosolic acid triggers mitochondria and
caspase-dependent apoptotic cell death in osteosarcoma MG-63 cells.
Phytother Res. 25:1354–1361. 2011.PubMed/NCBI
|
|
27
|
Lee MS, Cha EY, Thuong PT, Kim JY, Ahn MS
and Sul JY: Down-regulation of human epidermal growth factor
receptor 2/neu oncogene by corosolic acid induces cell cycle arrest
and apoptosis in NCI-N87 human gastric cancer cells. Biol Pharm
Bull. 33:931–937. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fujiwara Y, Komohara Y, Ikeda T and Takeya
M: Corosolic acid inhibits glioblastoma cell proliferation by
suppressing the activation of signal transducer and activator of
transcription-3 and nuclear factor-kappa B in tumor cells and
tumor-associated macrophages. Cancer Sci. 102:206–211. 2011.
View Article : Google Scholar
|
|
29
|
Horlad H, Fujiwara Y, Takemura K, Ohnishi
K, Ikeda T, Tsukamoto H, Mizuta H, Nishimura Y, Takeya M and
Komohara Y: Corosolic acid impairs tumor development and lung
metastasis by inhibiting the immunosuppressive activity of
myeloid-derived suppressor cells. Mol Nutr Food Res. 57:1046–1054.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lang SA, Gaumann A, Koehl GE, Seidel U,
Bataille F, Klein D, Ellis LM, Bolder U, Hofstaedter F, Schlitt HJ,
et al: Mammalian target of rapamycin is activated in human gastric
cancer and serves as a target for therapy in an experimental model.
Int J Cancer. 120:1803–1810. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Matsuzaki T, Yashiro M, Kaizaki R, Yasuda
K, Doi Y, Sawada T, Ohira M and Hirakawa K: Synergistic
antipro-liferative effect of mTOR inhibitors in combination with
5-fluorouracil in scirrhous gastric cancer. Cancer Sci.
100:2402–2410. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jackson C, Cunningham D and Oliveira J;
ESMO Guidelines Working Group: Gastric cancer: ESMO clinical
recommendations for diagnosis, treatment and follow-up. Ann Oncol.
20(Suppl 4): 34–36. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Glimelius B, Ekström K, Hoffman K, Graf W,
Sjödén PO, Haglund U, Svensson C, Enander LK, Linné T, Sellström H,
et al: Randomized comparison between chemotherapy plus best
supportive care with best supportive care in advanced gastric
cancer. Ann Oncol. 8:163–168. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lei X, Lv X, Liu M, Yang Z, Ji M, Guo X
and Dong W: Thymoquinone inhibits growth and augments
5-fluoro-uracil-induced apoptosis in gastric cancer cells both in
vitro and in vivo. Biochem Biophys Res Commun. 417:864–868. 2012.
View Article : Google Scholar
|
|
35
|
Tang D, Lotze MT, Kang R and Zeh HJ:
Apoptosis promotes early tumorigenesis. Oncogene. 30:1851–1854.
2011. View Article : Google Scholar
|
|
36
|
Bjornsti MA and Houghton PJ: The TOR
pathway: A target for cancer therapy. Nat Rev Cancer. 4:335–348.
2004. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wullschleger S, Loewith R and Hall MN: TOR
signaling in growth and metabolism. Cell. 124:471–484. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tomioka H, Mukohara T, Kataoka Y,
Ekyalongo RC, Funakoshi Y, Imai Y, Kiyota N, Fujiwara Y and Minami
H: Inhibition of the mTOR/S6 K signal is necessary to enhance
fluorouracil-induced apoptosis in gastric cancer cells with HER2
amplification. Int J Oncol. 41:551–558. 2012.PubMed/NCBI
|
